A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients
Related Experiment Video
Updated: Oct 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
1Division of Infectious Diseases, Hospital General, Public Health Department, Castellón, Spain.
Objective:
To compare adherence and clinical outcome with two modalities of highly active antiretroviral therapy (HAART), in HIV-infected patients.
Design:
Randomized, open-label, prospective study.
Setting:
Tertiary care centre in Spain.
Patients:
A total of 112 non-naive HIV-infected patients, recruited from March 1998 through August 1998, were studied.
Interventions:
Triple drug therapy with stavudine and lamivudine, plus indinavir or nelfinavir.
Main Outcome Measures:
Adherence, side-effects, and immunological, virological, and clinical efficacy of treatment were assessed at 3-month intervals.
Results:
After a median follow-up of 9 months, 32% of patients in the indinavir group versus 50% of those in the nelfinavir group showed adequate adherence in all clinical appointments (P= 0.0559). Adherence was superior in the nelfinavir group in every visit. After 6 months of treatment 48% of subjects in the indinavir group and 70% of those in the nelfinavir group exhibited adequate adherence (P= 0.0311). After 9 months 35% of patients in the indinavir group and 59% of those in the nelfinavir group showed adequate adherence (P= 0.0291). Side-effects provoked discontinuation of treatment in 34% of patients in the indinavir group and 12% of patients in the nelfinavir group (P= 0.0073). Immunological and virological efficacy were similar in both groups.
Conclusions:
Adherence to a HAART regimen with stavudine plus lamivudine plus nelfinavir was superior to a regimen with stavudine plus lamivudine plus indinavir. Side-effects provoked more discontinuation of treatment in the indinavir group than in the nelfinavir group.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Bioavailability Study Design: Healthy Subjects Versus Patients

